Skip to main content

Table 2 Clinical characteristics, immunohistochemical and molecular markers available and response to therapy of patients with grade 3B

From: EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment

  N Total Mutated EZH2 in FFPE (n = 6) Unmutated EZH2 in FFPE (n = 7) p-valor
(n = 13)
Clinical characteristics at diagnosis, n (%)
 Age at diagnosis, mean (range) 13 65 (30–85) 65 (42–84) 65 (30–85) 0.775
 Sex
  Female 13 4 (31) 3 (50) 1 (14) 0.266
  Male 9 (69) 3 (50) 6 (86)
 ECOG
  0–1 6 6 (100) 3 (100) 3 (100)  
 Stage
  I-II 13 3 (23) 1 (17) 2 (29) > 0.999
  III-IV 10 (77) 5 (83) 5 (71)
 FLIPI risk categories
  Low-Intermediate 9 5 (56) 1 (20) 4 (100) 0.048
  High 4 (44) 4 (80) 0
 Bulky mass 13 4 (31) 2 (33) 2 (29) > 0.999
 Extranodal 12 1 (8) 1 (20) 0 0.417
 Bone narrow infiltration 13 4 (31) 3 (50) 1 (14) 0.266
 B-symptoms 13 5 (39) 1 (17) 4 (57) 0.266
First-line R-CHOP therapy, n (%) 13     
  Complete remission   8 (62) 3 (60) 5 (71) 0.54
  Progression 0    NA
  Relapse 3 (23) 2 (33) 1 (14) 0.2
  Not assesseda 2 (15) 1 (17) 1 (14)  
Exitus, n (%)
  Yes 13 4 (31) 1 (17) 3 (43) 0.559
  No 9 (69) 5 (83) 4 (57)
  1. aData not included in Fisher’s exact test